Mast cells are immune cells that release substances such as histamine and tryptase. These substances are called mediators.

Mast cell activation syndrome (MCAS) involves recurring systemic episodes caused by mast cell mediator release. Consensus diagnosis combines a characteristic symptom pattern, objective evidence of activation and response to appropriate treatment.

Mast cell activation can be linked to allergy or a clonal mast cell disorder, or be idiopathic when no cause is identified. MCAS and mastocytosis are distinct diagnoses, although activation symptoms can occur in mastocytosis.

Episodes may involve flushing, itching, hives or swelling; abdominal cramps, diarrhoea or vomiting; wheeze or breathing difficulty; and a fall in blood pressure or fainting. Typical systemic episodes affect more than one body system.

Fatigue, headache and brain fog are less specific. Symptoms alone cannot establish MCAS, and other conditions can produce similar experiences.

A rash is not required for anaphylaxis. Seek urgent care for emergency signs rather than waiting for skin changes.

A clinical immunologist or allergist can assess the pattern, exclude alternatives and arrange suitable testing. Consensus criteria generally require all three: recurring characteristic systemic episodes; a documented rise in a mast cell mediator; and improvement with treatment directed at mediators.

Paired tryptase samples are commonly used: an acute sample soon after an episode and a baseline sample when well. A commonly used significant-rise threshold is acute tryptase greater than baseline × 1.2 + 2 ng/mL. A normal-range acute result can still meet that threshold if it rises sufficiently from a low baseline.

Ask in advance about collection timing and local laboratory requirements. Other mediator tests may be considered by a specialist. Testing must never delay emergency treatment.

A single normal baseline tryptase does not rule out an episode of activation, and an elevated baseline alone does not diagnose MCAS. Improvement with an antihistamine alone is also insufficient.

If criteria are not met, symptoms still deserve care and investigation. Broad symptom questionnaires or unvalidated commercial tests should not replace clinical assessment.

A plan may combine targeted medicines, avoidance of confirmed triggers and care for coexisting conditions. A specialist can explain expected benefits, uncertainty and when to review treatment.

Ask whether you need prescribed adrenaline and a written anaphylaxis action plan. Practise the prescribed device with a trainer or clinician, and make sure supporters know the plan.

For procedures, surgery or contrast imaging, discuss previous reactions with the treating team in advance. Do not assume every medicine or procedure is unsafe.

Regulation skills may help distress during non-emergency symptoms, but they do not treat anaphylaxis or replace medical treatment.

Food allergy, chronic urticaria, asthma, medication reactions and mastocytosis may need different investigations and treatment. Histamine intolerance is not another name for MCAS.

POTS, hypermobility, migraine, IBS, ME/CFS and MCAS are sometimes discussed together. Having one does not establish another, and the evidence for a single shared mechanism remains uncertain.

Breathing symptoms can have several causes, including asthma and inducible laryngeal obstruction (also called vocal cord dysfunction). New severe symptoms require appropriate care.

Immune & inflammatory: this is the most direct domain for mast cell mediator symptoms and specialist care.

Anxiety & autonomic: reactions and fear of reactions can affect daily life. Dizziness and palpitations need assessment; do not automatically label them anxiety or MCAS.

Laxity & connective tissue: accommodate joint problems when present. Hypermobility alone does not diagnose MCAS.

Pain & bodily sensitivity: provide separate migraine and pain care, and choose tolerated positioning and products.

Mood & mental health: uncertainty and restrictions can be distressing. Emotional support can accompany physical healthcare.

Sensory & neurodevelopmental: reduce sensory and communication demands. Neurodivergence or sensory sensitivity alone does not establish mast cell activation.

ALPIMS helps organise overlapping needs. It is not a diagnostic test, and these adjustments are not proof that one domain causes another.

Possible signs include suddenly difficult or noisy breathing, tongue or throat swelling, new voice changes during a reaction, or persistent dizziness or collapse. Anaphylaxis may occur without hives.

Use your prescribed adrenaline device immediately according to your action plan and call 000. If symptoms are not improving, follow the plan’s instructions for further adrenaline; another dose is commonly required after 5 minutes. Follow ambulance instructions.

Lie flat and do not stand or walk. If breathing is difficult, sit with legs outstretched. If unconscious but breathing, or vomiting, position on the side. If not breathing normally, begin CPR as directed by the emergency operator.

Antihistamines, asthma relievers and steroids are not substitutes for adrenaline. Do not wait for tests or symptom logging. Emergency assessment is needed even if adrenaline helps.

Medical information draws on these specialist resources. Practical prompts and ALPIMS adaptations are suggestions, not validated clinical tests. Linked organisations do not endorse ALPIMS.

This page does not diagnose MCAS or provide personalised treatment. Symptoms can overlap with many conditions; assessment should consider other explanations and coexisting illnesses.

Do not use this page to change medicine doses, undertake food challenges or replace an emergency action plan. Avoid unnecessary food restrictions and unsupported tests or treatments.

New, severe or changing symptoms need appropriate medical assessment. For immediate danger or a medical emergency in Australia, call 000.

This page has no forms and does not save personal answers. External websites have their own privacy policies.